Autosomal Clinical Trials in Rochester, Minnesota
8 recruitingRochester, Minnesota
Showing 1–8 of 8 trials
Recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
AstraZeneca40 enrolled15 locationsNCT07228364
Recruiting
Phase 2
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Vertex Pharmaceuticals Incorporated24 enrolled40 locationsNCT07161037
Recruiting
Phase 3
A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)
Autosomal Recessive Polycystic Kidney (ARPKD)
Otsuka Pharmaceutical Development & Commercialization, Inc.20 enrolled23 locationsNCT04782258
Recruiting
Phase 2
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease
AbbVie240 enrolled75 locationsNCT06902558
Recruiting
A Prospective Observational Study of Foam Sclerotherapy .
Autosomal Dominant Polycystic KidneyRenal CystAutosomal Dominant Polycystic Liver Disease+1 more
Mayo Clinic100 enrolled1 locationNCT04111692
Recruiting
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease
Mayo Clinic40 enrolled1 locationNCT04344769
Recruiting
NOX4 and Related Biomarkers in ADPKD
Autosomal Dominant Polycystic Kidney Disease
Mayo Clinic60 enrolled1 locationNCT04630613
Recruiting
Phase 2
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Arterial calcificationPseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency+2 more
Inozyme Pharma200 enrolled5 locationsNCT06462547